Buy Neurontin (Gabapentin) medication at very competitive price. No prescription! Fast delivery!
Two studies recently published in The Journal of the American Medical Association, reported that Parke-Davis’ Neurontin(R) (gabapentin capsules) significantly reduced chronic neuropathic pain. One study examined the effects of Neurontin on patients with diabetic peripheral neuropathy (DPN), a chronic, often painful condition that affects approximately half of the estimated 1.5 million diabetes mellitus patients in Canada. A companion study examined the use of Neurontin in patients suffering from post-herpetic neuralgia, the chronic neuropathic pain condition that can follow shingles (herpes zoster).
Results of the national, multi-centre DPN study demonstrated that patients suffering from diabetic peripheral neuropathy experienced a significant reduction in pain after treatment with the medication and that 26 percent of those patients treated with Neurontin were painless at the end of the trial compared to 15 percent of patients treated with placebo. This difference was statistically significant in nature.
Findings of the national, multi-centre PHN study indicated that patients suffering from the condition experienced a statistically significant reduction in average daily pain after treatment with Neurontin. Importantly, almost twice as many patients treated with Neurontin (16 percent) were pain-free against those treated with placebo (8.8 percent) at the end of the trial. Both studies also showed that patients receiving Neurontin experienced enhancement in sleep and overall quality of life.
The PHN study was a multi-centre, randomized; double-blind study conducted over a treatment period of eight weeks and involved 229 PHN patients.
The results of this trial are particularly encouraging, given the hundreds of thousands of people suffering from this debilitating and very painful condition, according to R. Norman Harden, M.D., director of the Centre for Pain Studies, Rehabilitation Institute of Chicago and "Further, the age distribution of patients with PHN includes an unequal in number of older patients, which is a difficult population to treat."
PHN is a syndrome of often intractable pain following herpes zoster, a condition commonly what we call as shingles. It is estimated that 10 to 20 percent of Canadians will be affected by herpes zoster in their lifetime and in the majority of patients, the condition is characterised by intense pain that has been described by sufferers as burning, deep aching, tearing and electric shock-like.